The  	The  	 DT	O
future  	future  	 NN	O
is  	is  	 VBZ	O
predetermined  	predetermined  	 VBN	O
in  	in  	 IN	O
severe  	severe  	 JJ	O
sepsis 	sepsis 	 NN	O
,  	,  	 ,	O
so  	so  	 RB	O
what  	what  	 WP	O
are  	are  	 VBP	O
the  	the  	 DT	O
implications 	implications 	 NNS	B-NP
?  	?  	 .	O
A  	A  	 DT	O
high  	high  	 JJ	O
rate  	rate  	 NN	O
of  	of  	 IN	O
death  	death  	 NN	O
from  	from  	 IN	O
septic  	septic  	 JJ	B-NP
shock  	shock  	 NN	I-NP
persists  	persists  	 VBZ	O
despite  	despite  	 IN	O
general  	general  	 JJ	O
improvements  	improvements  	 NNS	B-NP
in  	in  	 IN	O
care 	care 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
relative  	relative  	 JJ	B-NP
failure  	failure  	 NN	I-NP
of  	of  	 IN	O
mechanistically  	mechanistically  	 VBG	O
based  	based  	 VBN	O
therapies  	therapies  	 NNS	O
in  	in  	 IN	O
various  	various  	 JJ	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
should  	should  	 MD	O
also  	also  	 RB	O
trigger  	trigger  	 VB	O
a  	a  	 DT	O
reconsideration  	reconsideration  	 NN	B-NP
of  	of  	 IN	O
such  	such  	 JJ	O
mechanistic  	mechanistic  	 JJ	B-NP
approaches 	approaches 	 NNS	I-NP
.  	.  	 .	O
Despite  	Despite  	 IN	O
reversion  	reversion  	 NN	O
of  	of  	 IN	O
shock  	shock  	 NN	O
by  	by  	 IN	O
hydrocortisone 	hydrocortisone 	 NN	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
similar  	similar  	 JJ	O
death  	death  	 NN	B-NP
rate  	rate  	 NN	I-NP
compared  	compared  	 VBN	O
with  	with  	 IN	O
nonsteroid-treated  	nonsteroid-treated  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
suggests  	suggests  	 VBZ	O
that  	that  	 IN	O
factors  	factors  	 NNS	O
other  	other  	 JJ	O
than  	than  	 IN	O
shock  	shock  	 NN	O
itself  	itself  	 PRP	O
are  	are  	 VBP	O
responsible  	responsible  	 JJ	O
for  	for  	 IN	O
death 	death 	 NN	O
.  	.  	 .	O
This  	This  	 DT	O
may  	may  	 MD	O
be  	be  	 VB	O
predetermined  	predetermined  	 VBN	O
and  	and  	 CC	O
relate  	relate  	 VBP	O
to  	to  	 TO	O
gene  	gene  	 NN	B-NP
variants 	variants 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
functionality  	functionality  	 NN	B-NP
of  	of  	 IN	I-NP
gene  	gene  	 NN	I-NP
expression 	expression 	 NN	I-NP
,  	,  	 ,	O
age 	age 	 NN	O
,  	,  	 ,	O
an  	an  	 DT	O
association  	association  	 NN	O
with  	with  	 IN	O
chronic  	chronic  	 JJ	B-NP
diseases  	diseases  	 NNS	I-NP
such  	such  	 JJ	O
as  	as  	 IN	O
diabetes  	diabetes  	 NN	O
and  	and  	 CC	O
cancer 	cancer 	 NN	O
,  	,  	 ,	O
or  	or  	 CC	O
perhaps  	perhaps  	 RB	O
the  	the  	 DT	O
treatments  	treatments  	 NNS	O
being  	being  	 VBG	O
given  	given  	 VBN	O
for  	for  	 IN	O
these  	these  	 DT	O
diseases 	diseases 	 NNS	O
.  	.  	 .	O
These  	These  	 DT	O
aspects  	aspects  	 NNS	O
are  	are  	 VBP	O
discussed  	discussed  	 VBN	O
in  	in  	 IN	O
this  	this  	 DT	O
review  	review  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
light  	light  	 NN	O
of  	of  	 IN	O
arguments  	arguments  	 NNS	O
that  	that  	 WDT	O
support  	support  	 VBP	O
a  	a  	 DT	O
hypothesis  	hypothesis  	 NN	O
of  	of  	 IN	O
outcome  	outcome  	 NN	B-NP
predetermination 	predetermination 	 NN	I-NP
.  	.  	 .	O
Not  	Not  	 RB	O
only  	only  	 RB	O
constitutive  	constitutive  	 JJ	B-NP
factors 	factors 	 NNS	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
also  	also  	 RB	O
acute  	acute  	 JJ	O
and  	and  	 CC	O
chronic  	chronic  	 JJ	B-NP
environmental  	environmental  	 JJ	I-NP
factors  	factors  	 NNS	I-NP
may  	may  	 MD	O
be  	be  	 VB	O
responsible 	responsible 	 JJ	O
.  	.  	 .	O
An  	An  	 DT	O
important  	important  	 JJ	O
consequence  	consequence  	 NN	O
would  	would  	 MD	O
be  	be  	 VB	O
the  	the  	 DT	O
ability  	ability  	 NN	B-NP
to  	to  	 TO	O
perform  	perform  	 VB	O
early  	early  	 JJ	O
prognostication  	prognostication  	 NN	B-NP
in  	in  	 IN	O
an  	an  	 DT	O
individual  	individual  	 JJ	B-NP
patient  	patient  	 NN	I-NP
using  	using  	 VBG	O
biomarkers 	biomarkers 	 NNS	B-NP
.  	.  	 .	O
On  	On  	 IN	O
this  	this  	 DT	O
basis 	basis 	 NN	O
,  	,  	 ,	O
new  	new  	 JJ	O
therapies  	therapies  	 NNS	O
could  	could  	 MD	O
be  	be  	 VB	O
tested  	tested  	 VBN	O
to  	to  	 TO	O
reduce  	reduce  	 VB	O
mortality  	mortality  	 NN	B-NP
rates  	rates  	 NNS	I-NP
with  	with  	 IN	O
the  	the  	 DT	O
response  	response  	 NN	O
and  	and  	 CC	O
toxicity  	toxicity  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
therapies  	therapies  	 NNS	O
being  	being  	 VBG	O
predefined  	predefined  	 NNS	O
using  	using  	 VBG	O
pharmacogenetic  	pharmacogenetic  	 JJ	B-NP
testing 	testing 	 NN	I-NP
.  	.  	 .	O
